ProKidney (PROK) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ProKidney (PROK) has outperformed Tevogen (TVGN) over the past year, losing 52.5% versus a loss of 73.8%. ProKidney is the larger company by market cap ($415.2 million vs $405.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROK | TVGN |
|---|---|---|
| Share price | $1.04 | $5.90 |
| Market cap | $415.21M | $405.20M |
| 1-day change | -1.89% | -6.35% |
| YTD return | -53.57% | -64.35% |
| 1-year return | -52.51% | -73.84% |
| 5-year return | -89.49% | — |
| EPS (TTM) | $-0.61 | $-7.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $893.00K | — |
| Revenue growth (YoY) | +1075.00% | — |
| Net income (latest FY) | $-68.99M | $-26.28M |
| Operating margin | -18477.83% | — |
| Net margin | -7725.20% | — |
| 52-week high | $2.65 | $24.90 |
| 52-week low | $0.87 | $3.64 |
| Distance from 52-week high | -60.75% | -76.31% |
| Analyst consensus | buy | — |
| Avg. price target upside | +525.00% | — |
| Average volume | 1.44M | 7.94K |
| Shares outstanding | 209.63M | 68.68M |
| Employees | 231 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PROK has outperformed TVGN by 21.3 percentage points over the past year.
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
PROK vs TVGN FAQ
Which is bigger, ProKidney or Tevogen?
ProKidney (PROK) is larger, with a market capitalization of $415.21M compared with $405.20M for Tevogen (TVGN).
Which stock has performed better over the past year, PROK or TVGN?
PROK returned -52.51% over the past 12 months, compared with -73.84% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are ProKidney and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.